Table 3.
Details on CMV infection during 36 months
| Characteristic | Valganciclovir (n = 60) | Valacyclovir (n = 59) | P Value |
|---|---|---|---|
| CMV Disease | 5 (9) | 1 (2) | 0.115a |
| CMV Disease by D/R status | |||
| D+/R- | 3 (49) | 0 (0) | 0.125 |
| D+/R+ | 2 (5) | 1 (2) | 0.555 |
| D−/R+ | 0 (0) | 0 (0) | – |
| CMV DNAemia | 21 (36) | 24 (42) | 0.361a |
| CMV DNAemia by D/R status | |||
| D+/R- | 4 (64) | 2 (50) | 0.986 |
| D+/R+ | 14 (32) | 21 (45) | 0.180 |
| D−/R+ | 5 (50) | 1 (17) | 0.264 |
| Peak viral load (copies/mL) | 350 (100–6150) | 850 (100–1650) | 0.982 |
| Duration of CMV DNAemia (d) | 40 (27–78) | 31 (15–69) | 0.270 |
Data are number of patients (percentage) or median and interquartile range. CMV, cytomegalovirus; D, donor; R, recipient
aCMV Disease: adjusted hazard ratio, 4.96; 95% confidence interval, 0.57–43.1; P = 0.147; CMV DNAemia: adjusted hazard ratio, 0.78; 95% confidence interval, 0.43–1.42; P = 0.418 by multivariate Cox proportional hazard model after adjustment for calcineurin inhibitor, induction therapy, and advanced chronic histologic damage in donor biopsy